Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

Biotech Partners to Focus on Drugs Targeting G-Protein Coupled Receptors

By BiotechDaily International staff writers
Posted on 05 Nov 2012
Print article
An agreement between the French company Domain Therapeutics (Illkirch-Strasbourg, France) and Japanese Ono Pharmaceutical Co., Ltd. (Osaka, Japan) is designed to promote the discovery of small molecules targeting G-Protein Coupled Receptors (GPCRs).

GPCRs are not only the largest protein family in the human genome but also the single biggest target for therapeutic agents. Ligand binding to these receptors activates their associated G protein, which then activates an effector enzyme to generate an intracellular second messenger. All GPCRs contain seven membrane-spanning regions with their N-terminal segment on the external face and their C-terminal segment on the cytosolic face of the plasma membrane. This large receptor family includes light-activated receptors (rhodopsins) in the eye and thousands of odorant receptors in the nose, as well as numerous receptors for various hormones and neurotransmitters. Although these receptors are activated by different ligands and may mediate different cellular responses, they all mediate a similar signaling pathway.

Under the terms of the collaborative agreement for development of GPRC-directed drugs, Ono Pharmaceutical will provide Domain Therapeutics with an upfront payment and provide research funding for collaborative research programs and success-based milestones. Domain Therapeutics will receive royalties on sales of the products.

Domain Therapeutics will apply its proprietary DTect-All GPCR drug discovery platform and utilize its expertise in GPCR medicinal chemistry and pharmacology to design and optimize small molecules into drug candidates having activity against GPCRs selected by Ono Pharmaceutical.

Ono Pharmaceutical will then have worldwide exclusive rights to develop and commercialize any pharmaceutical product arising out of the drug discovery collaboration.

“This collaboration with Ono further confirms the value of our differentiated drug discovery process and of our expertise in the field of GPCRs. It constitutes an important step towards the objective of Domain Therapeutics to collaborate with pharma partners on integrated projects, from target to drug candidate,” said Pascal Neuville, CEO of Domain Therapeutics. “We are delighted to be collaborating with Ono, which is recognized as a leading Japanese pharmaceutical company.”

Dr. Kazuhito Kawabata, executive director of discovery and research at Ono Pharmaceutical, said, “We highly appreciate Domain Therapeutics’ DTect-All technology and strongly believe that the company is the partner of choice to identify GPCR drugs. This collaboration will strengthen Ono’s drug discovery capability in research areas of Ono’s expertise with significant unmet medical needs. We are expecting that innovative drugs will be created through this collaboration.”

Related Links:

Ono Pharmaceutical
Domain Therapeutics


Print article

Channels

Genomics/Proteomics

view channel
Image: A dark field photomicrograph showing the spirochete bacterium Borrelia burgdorferi, the pathogen responsible for causing Lyme disease (Photo courtesy of the CDC).

Statins May Help Block Transmission of Lyme Disease

A recent study found that treatment with cholesterol-lowering statins reduced the number of Borrelia burgdorferi bacteria in rodents, which helped to block transmission of Lyme disease. Lyme disease... Read more

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.